Abstract: FR-PO0277
Risk of CKD and ESRD in Patients with Kidney Stones: A Systematic Review and Meta-Analysis with 7,045,880 Participants
Session Information
- Bone and Mineral Metabolism: Clinical Epidemiology and Outcomes
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Bone and Mineral Metabolism
- 502 Bone and Mineral Metabolism: Clinical
Authors
- Alshareef, Abdulmueti, Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States
- Ahmed, Omar Ahmed Saad, Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States
- Abudrea, Mutaz Bellah, AdventHealth Tampa, Tampa, Florida, United States
- Elkhadar, Abdulmohimen Adel M, University of Tripoli, Tripoli, Tripoli District, Libya
- Lieske, John C., Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States
Background
Kidney stones is one of the most common diseases of the urinary system, affecting 1–20% of the population worldwide. It is considered a systemic disorder that may be associated with various comorbidities. Chronic kidney disease (CKD) is a progressive condition characterized by a gradual loss of kidney function. The U.S. National Kidney Foundation classifies CKD into five stages based on severity. Stage 5 CKD, also known as end-stage renal disease (ESRD), requires renal replacement therapy such as dialysis or kidney transplantation.
Methods
Following PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), we conducted a systematic review and meta-analysis to assess the risk of CKD in patients with a history of kidney stone events. A comprehensive literature search was performed using electronic databases including PubMed, Google Scholar, Scopus, and Web of Science, from inception to May 2025. We included only original studies that investigated the odds ratio (OR), relative risk (RR), or hazard ratio (HR) for CKD in patients with a history of nephrolithiasis or urolithiasis. Comprehensive Meta-Analysis (CMA) V3 software was used for the analysis.
Results
Fourteen studies, comprising a total of 7,024,895 patients, were included in our meta-analysis. The pooled analysis of eight studies reporting HRs showed that the overall hazard ratio for CKD in patients with a history of kidney stones was 1.44 (95% CI: 1.29–1.60). Additionally, the pooled HR for ESRD from five studies was 1.79 (95% CI: 1.29–1.60) -]. The combined pooled analysis for both CKD and ESRD yielded an HR of 1.52 (95% CI: 1.39–1.66). The overall OR for CKD based on three studies was 1.91 (95% CI: 1.63–2.25).
In subgroup analysis, the highest risk of CKD was observed in the American population, with an HR of 1.47 (95% CI: 1.23–1.76). The HR for the Asian subgroup was 1.44 (95% CI: 1.19–1.95), and for the European population, it was 1.44 (95% CI: 1.29–1.60). No publication bias was detected.
Conclusion
Kidney stones are associated with an increased likelihood risk of CKD, regardless of the patient population. They have also been associated with ESKD. Further studies are needed to explore the cause and effect of this relationship, and the potential modifying effect of stone composition.